Teadusuuringud

ERSPC eesnäärmevähi riski kalkulaator: väljatöötamisest kasutamiseni kliinilises praktikas
Väljatöötamine
Rakendamine
Uued omadused
Valideerimine
Kasutamine kliinilises praktikas

ERSPC: sõeluuringuga seotud publitseeritud leiud (veel)

2010-2011

Guazzoni, G., Nava, L., Lazzeri, M., et al. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: Results of a prospective study in a clinical setting. Eur Urol, 2011, 60(2), 214−222.

Vickers, A. J., Cronin, A. M., Roobol, M. J., Savage, C. J., Peltola, M., Pettersson, K., et al. A four-kallikrein panel predicts prostate cancer in men with recent screening: Data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam. Clin Cancer Res, 2010, 16(12): 3232−3239.

Bangma, C. H., van Schaik, R. H., Blijenberg, B. G., Roobol, M. J., Lilja, H., Stenman, U. H. On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer. Eur J Cancer, 2010, 46(17), 3109−3119.

Roobol, M. J., Steyerberg, E. W., Kranse, R., Wolters, T., van den Bergh, R. C., Bangma, C. H., et al. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. Eur Urol 2010, 57(1), 79−85.

Jansen, F. H., van Schaik, R. H. N., Kurstjens, J., Horninger, W., Klocker, H., Bektic, J., Wildhagen, M. F., Roobol, M. J., Bangma, C. H., Georg, B. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol, 2010, 57(6), 921–927.

(veel)

Kontaktandmed

Monique Roobol
Riskikalkulaatori administraator

info@prostatecancer-riskcalculator.com

Teie tagasiside

Rääkige meile, mida te arvate riskikalkulaatoritest ja milline on olnud teie kasutuskogemus.

Me oleme teile tagasiside eest tänulikud.